Head-to-head review of Moderna (NASDAQ:MRNA) vs. Surrozen (NASDAQ:SRZN)

Modern (NASDAQ:ARNMGet an assessment) and Surrozen (NASDAQ:SRZNGet an assessment) are two medical companies, but which company is better? We’ll compare the two companies based on institutional ownership strength, risk, analyst recommendations, dividends, valuation, earnings, and profitability.

Analyst Notes

This is a summary of the current ratings and price targets for Moderna and Surrozen, as provided by MarketBeat.

Sales Ratings Hold odds Buy reviews Strong buy odds Rating
Modern 1 8 4 0 2.23
surrozen 0 1 2 0 2.67

Moderna currently has a consensus target price of $228.00, suggesting a potential upside of 56.85%. Surrozen has a consensus target price of $19.50, suggesting a potential upside of 480.36%. Given Surrozen’s stronger consensus rating and higher likely upside, analysts clearly think Surrozen is more favorable than Moderna.

Risk and Volatility

Moderna has a beta of 1.7, suggesting its stock price is 70% more volatile than the S&P 500. By comparison, Surrozen has a beta of 0.89, suggesting its stock price is 11% less volatile than the S&P 500.


This table compares Moderna’s and Surrozen’s net margins, return on equity, and return on assets.

Net margins Return on equity return on assets
Modern 64.77% 121.86% 65.53%
surrozen N / A -47.50% -32.51%

Valuation and benefits

This table compares the gross revenue, earnings per share (EPS), and valuation of Moderna and Surrozen.

Gross revenue Price/sales ratio Net revenue Earnings per share Price/earnings ratio
Modern $18.47 billion 3.13 $12.20 billion $34.03 4.27
surrozen N / A N / A -$54.65 million N / A N / A

Moderna has higher revenue and profit than Surrozen.

Institutional and insider ownership

61.2% of Moderna’s shares are held by institutional investors. Comparatively, 74.3% of Surrozen’s shares are held by institutional investors. 17.3% of Moderna’s stock is held by company insiders. Strong institutional ownership indicates that large fund managers, hedge funds, and endowments believe a company is poised for long-term growth.


Moderna beats Surrozen on 8 of the 11 factors compared between the two stocks.

Moderna Company Profile (Get an assessment)

Moderna, Inc., a biotechnology company, discovers, develops and commercializes messenger RNA-based therapies and vaccines for the treatment of infectious diseases, immuno-oncology, rare diseases, cardiovascular diseases and diseases autoimmune diseases in the United States, Europe and internationally. Its respiratory vaccines include vaccines against COVID-19, influenza, respiratory syncytial virus, endemic HCoV and hMPV+PIV3; latent vaccines include vaccines against cytomegalovirus, Epstein-Barr virus, human immunodeficiency virus, herpes simplex virus, and varicella zoster virus; and public health vaccines include Zika and Nipah vaccines. The company also offers systemic and cell surface secreted therapies; cancer vaccines, such as personalized cancer vaccines, KRAS and checkpoints; intratumoral immuno-oncology products; localized, intracellular systemic and pulmonary inhaled regenerative therapies. It has strategic alliances with AstraZeneca PLC; Merck & Co., Inc.; Vertex Pharmaceuticals Incorporated; Vertex Pharmaceuticals (Europe) Limited; Carisma Therapeutics, Inc.; Metagenomi, Inc.; the Defense Advanced Research Projects Agency; Advanced Biomedical Research and Development Authority; Institute for Life-Changing Medicines; and the Bill & Melinda Gates Foundation, as well as a collaboration and licensing agreement with Chiesi Farmaceutici SPA The company was formerly known as Moderna Therapeutics, Inc. and changed its name to Moderna, Inc. in August 2018. Moderna, Inc. was founded in 2010 and is based in Cambridge, Massachusetts.

Surrozen Company Profile (Get an assessment)

Surrozen, Inc., a biotechnology company, discovers and develops drug candidates to selectively modulate the Wnt pathway for tissue repair and regeneration. It develops tissue-specific antibodies with applications in various disease areas including bowel, liver, retina, cornea, lung, kidney, cochlea, skin, pancreas diseases and the central nervous system. Its products in development include SZN-043, a tissue-specific R-spondin mimetic for the treatment of severe liver disease; and SZN-1326, a bispecific full human antibody that directly modulates Wnt signaling in the target tissue by binding to particular Frizzled and LRP receptors that are expressed in the intestinal crypts. Surrozen, Inc. was founded in 2015 and is headquartered in South San Francisco, CA.

Get news and reviews for Moderna Daily – Enter your email address below to receive a concise daily summary of breaking news and analyst ratings for Moderna and related companies with MarketBeat.com’s free daily email newsletter.

Comments are closed.